Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Clinical trial NCT06607692 · RECRUITING

Trial details

NCT number: NCT06607692
Sponsor: Fundación de investigación HM
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor Cancer Medulloblastoma High Risk Neuroblastoma High Grade Gliomas Meningioma Paraganglioma Pheochromocytoma Neuroendocrine Tumours (NET)Adrenal Tumours DIPG Glioblastoma Glioblastoma (GBM)

Start date: 2024-09-20
Primary completion: 2029-07-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.